Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.64 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937554 | 0.92 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL936442 | 0.89 | PIK3CG (0.68) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL938152 | 0.88 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL938220 | 0.86 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL936615 | 0.86 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL938043 | 0.86 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL936168 | 0.84 | PIK3CG (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL936914 | 0.84 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL937360 | 0.84 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 | |
| SCHEMBL936502 | 0.83 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CAPIK3CBPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | claimed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | claimed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | claimed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | claimed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | PIK3C3, PIK3R3, PIK3R5 | PIK3CG 11/4885PIK3CD 6/4885PIK3CA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.